Clovis Oncology Inc. (CLVS) Stock Price Up 10.9%
Clovis Oncology Inc. (NASDAQ:CLVS)’s share price rose 10.9% during trading on Friday . The stock traded as high as $17.80 and last traded at $17.12, with a volume of 1,989,384 shares trading hands. The stock had previously closed at $15.44.
CLVS has been the topic of several recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 price target on shares of Clovis Oncology in a research note on Tuesday, April 12th. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Thursday, April 14th. Janney Montgomery Scott reissued a “buy” rating on shares of Clovis Oncology in a research note on Wednesday, April 13th. Vetr lowered Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 target price on the stock. in a research note on Wednesday, May 25th. Finally, SunTrust Banks Inc. initiated coverage on Clovis Oncology in a research note on Friday. They set a “buy” rating on the stock. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Clovis Oncology currently has a consensus rating of “Buy” and a consensus target price of $29.25.
The stock’s 50 day moving average price is $14.14 and its 200-day moving average price is $16.51. The company’s market cap is $668.28 million.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share for the quarter, topping the consensus estimate of ($2.39) by $0.22. Clovis Oncology’s revenue for the quarter was up NaN% on a year-over-year basis. During the same period in the previous year, the company posted ($1.86) EPS. On average, equities research analysts expect that Clovis Oncology Inc. will post ($8.00) earnings per share for the current fiscal year.
Other institutional investors recently added to or reduced their stakes in the company. Trexquant Investment LP bought a new position in Clovis Oncology during the fourth quarter valued at $3,170,000. Rhumbline Advisers increased its position in Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 1,880 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock valued at $1,806,000 after buying an additional 889 shares during the last quarter.
Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.